Marshall Wace LLP lifted its position in shares of Braskem S.A. (NYSE:BAK - Free Report) by 14.3% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 787,348 shares of the company's stock after buying an additional 98,406 shares during the period. Marshall Wace LLP owned 0.20% of Braskem worth $3,039,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. HighTower Advisors LLC boosted its position in shares of Braskem by 19.4% in the fourth quarter. HighTower Advisors LLC now owns 19,213 shares of the company's stock worth $74,000 after acquiring an additional 3,126 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Braskem by 876.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,427 shares of the company's stock valued at $40,000 after purchasing an additional 4,871 shares during the last quarter. State Street Corp boosted its holdings in shares of Braskem by 2.3% in the 3rd quarter. State Street Corp now owns 228,110 shares of the company's stock valued at $1,674,000 after purchasing an additional 5,124 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Braskem during the 4th quarter worth $44,000. Finally, Virtu Financial LLC purchased a new position in shares of Braskem in the 3rd quarter worth $88,000.
Braskem Stock Up 2.9 %
Shares of Braskem stock traded up $0.11 during trading hours on Friday, hitting $3.69. The company's stock had a trading volume of 159,838 shares, compared to its average volume of 855,569. The business has a fifty day moving average of $3.66 and a 200 day moving average of $4.45. Braskem S.A. has a 1-year low of $2.85 and a 1-year high of $9.05. The company has a market capitalization of $1.47 billion, a PE ratio of -1.04 and a beta of 1.80.
Braskem (NYSE:BAK - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.01). The company had revenue of $3.28 billion during the quarter, compared to analyst estimates of $3.52 billion. Braskem had a negative net margin of 9.88% and a negative return on equity of 439.59%. On average, sell-side analysts anticipate that Braskem S.A. will post -0.77 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Scotiabank downgraded Braskem from a "sector outperform" rating to a "sector perform" rating in a research report on Monday, March 3rd.
View Our Latest Analysis on BAK
About Braskem
(
Free Report)
Braskem SA, together with its subsidiaries, produces and sells thermoplastic resins. The company operates through three segments: Brazil, United States and Europe, and Mexico. The Brazil segment produces and sells olefins, including ethylene, polymer and chemical grade propylene, butadiene, and butene-1; benzene, toluene, and xylenes products; fuels, such as automotive gasoline, liquefied petroleum gas, ethyl tertiary-butyl ether, and methyl tertiary-butyl ether; intermediates, such as cumene; aliphatics, aromatics, and hydrogenated solvents; and specialties comprising isoprene, dicyclopentadiene, piperylene, nonene, tetramer, polyisobutylene, and hydrocarbon resins.
Featured Stories

Before you consider Braskem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Braskem wasn't on the list.
While Braskem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.